{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:16:37Z","timestamp":1783566997760,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009584","name":"Toyota Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008397","name":"Velux Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Peptides"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.regpep.2012.12.012","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T12:13:47Z","timestamp":1357906427000},"page":"17-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs"],"prefix":"10.1016","volume":"181","author":[{"given":"L.","family":"Simonsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.regpep.2012.12.012_bb0005","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.regpep.2012.12.012_bb0010","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2012.12.012_bb0015","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2012.12.012_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.regpep.2012.12.012_bb0025","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9\u201339)-amide an antagonist at the glucagon-like peptide 1-(7\u201336)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"Goke","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.regpep.2012.12.012_bb0030","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00125-005-0128-9","article-title":"Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs","volume":"49","author":"Simonsen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2012.12.012_bb0035","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.regpep.2012.12.012_bb0040","doi-asserted-by":"crossref","first-page":"21201","DOI":"10.1074\/jbc.272.34.21201","article-title":"High potency antagonists of the pancreatic glucagon-like peptide-1 receptor","volume":"272","author":"Montrose-Rafizadeh","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.regpep.2012.12.012_bb0045","doi-asserted-by":"crossref","first-page":"13188","DOI":"10.1021\/bi010902s","article-title":"Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states","volume":"40","author":"Neidigh","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.regpep.2012.12.012_bb0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0167-0115(95)00063-H","article-title":"Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7\u201336) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides","volume":"58","author":"Hupe-Sodmann","year":"1995","journal-title":"Regul Pept"},{"key":"10.1016\/j.regpep.2012.12.012_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2002-29087","article-title":"Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4","volume":"110","author":"Thum","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.regpep.2012.12.012_bb0060","first-page":"E458","article-title":"Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig","volume":"271","author":"Deacon","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.regpep.2012.12.012_bb0065","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/BF00274797","article-title":"Pancreatic and intestinal processing of proglucagon in man","volume":"30","author":"Orskov","year":"1987","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2012.12.012_bb0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI115012","article-title":"Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine","volume":"87","author":"Orskov","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.regpep.2012.12.012_bb0075","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2337\/db10-1790","article-title":"Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function","volume":"60","author":"Kielgast","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2012.12.012_bb0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0026-0495(94)90164-3","article-title":"Effect of glucagon-like peptide-1 (proglucagon 78\u2013107amide) on hepatic glucose production in healthy man","volume":"43","author":"Hvidberg","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.regpep.2012.12.012_bb0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.regpep.2012.12.012_bb0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0167-0115(03)00120-4","article-title":"The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity","volume":"114","author":"Doyle","year":"2003","journal-title":"Regul Pept"},{"key":"10.1016\/j.regpep.2012.12.012_bb0095","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.regpep.2012.12.012_bb0100","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1055\/s-2007-1002190","article-title":"Renal catabolism of truncated glucagon-like peptide 1","volume":"25","author":"Ruiz-Grande","year":"1993","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.regpep.2012.12.012_bb0105","series-title":"Exenatide Pharmacokinetics in Patients with Mild to Moderate Renal Dysfunction and End Stage Renal Disease","author":"Linnebjerg","year":"2005"},{"key":"10.1016\/j.regpep.2012.12.012_bb0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/138920006776873490","article-title":"Investigation of exenatide elimination and its in vivo and in vitro degradation","volume":"7","author":"Copley","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.regpep.2012.12.012_bb0115","first-page":"F460","article-title":"Transport and hydrolysis of glucagon in the proximal nephron","volume":"251","author":"Peterson","year":"1986","journal-title":"Am J Physiol"},{"key":"10.1016\/j.regpep.2012.12.012_bb0120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","article-title":"Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells","volume":"141","author":"Schlatter","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.regpep.2012.12.012_bb0125","article-title":"Long-Term Metabolic Benefits of Exenatide in Mice Are Mediated Solely Via the Known glucagon-like peptide 1 receptor (GLP-1)","volume":"60","author":"Tatarkiewicz","year":"2011","journal-title":"Diabetes"},{"issue":"Pt 1","key":"10.1016\/j.regpep.2012.12.012_bb0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/bj3100203","article-title":"Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas","volume":"310","author":"Widmann","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.regpep.2012.12.012_bb0135","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.regpep.2012.12.012_bb0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.regpep.2007.10.001","article-title":"Protective effects of GLP-1 analogues exendin-4 and GLP-1(9\u201336) amide against ischemia\u2013reperfusion injury in rat heart","volume":"146","author":"Sonne","year":"2008","journal-title":"Regul Pept"}],"container-title":["Regulatory Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016701151300013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016701151300013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:17:30Z","timestamp":1759072650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016701151300013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":28,"alternative-id":["S016701151300013X"],"URL":"https:\/\/doi.org\/10.1016\/j.regpep.2012.12.012","relation":{},"ISSN":["0167-0115"],"issn-type":[{"value":"0167-0115","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs","name":"articletitle","label":"Article Title"},{"value":"Regulatory Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.regpep.2012.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}